• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Repeated infusions of DDAVP induce low response of FVIII and vWF but not of plasminogen activators.

作者信息

Vicente V, Estellés A, Laso J, Moraleda J M, Rivera J, Aznar J

机构信息

Centro de Investigación, Hospital La Fe, Valencia, Spain.

出版信息

Thromb Res. 1993 Apr 15;70(2):117-22. doi: 10.1016/0049-3848(93)90152-e.

DOI:10.1016/0049-3848(93)90152-e
PMID:8322282
Abstract

Although the vasopressin analogue desamino-d-arginine vasopressin (DDAVP) induces a very well characterized increase in factor VIII (FVIII), von Willebrand factor (vWF), tissue plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), the mechanism(s) by which DDAVP enhances the plasma levels of these proteins is poorly understood. Some clinical evidence suggests that certain patients repeatedly treated with DDAVP at closely spaced intervals become progressively unresponsive (tachyphylaxis). In order to investigate the effect of repeated DDAVP infusion on the behaviour of FVIII, vWF, t-PA and u-PA, we infused three different doses of DDAVP (0.3 microgram/Kg) to six healthy volunteers (19-26 years old, mean 22) at 12-hour intervals. Blood samples were collected immediately before and after DDAVP. The second and third infusion of DDAVP induced a low response of FVIII and vWF. In contrast, t-PA and u-PA exhibited a consistent response after each DDAVP infusion. If the progressive decrease of FVIII and vFW response observed in healthy subjects after repeated doses of DDAVP at 12-hour intervals is extended to haemophiliacs and von Willebrand's patients, the usefulness of desmopressin may be limited when these proteins must be raised therapeutically for a prolonged period of time. Finally, our results suggest that the mechanism for regulating the release of vWF and plasminogen activators in the conditions of our study are not dependent.

摘要

相似文献

1
Repeated infusions of DDAVP induce low response of FVIII and vWF but not of plasminogen activators.
Thromb Res. 1993 Apr 15;70(2):117-22. doi: 10.1016/0049-3848(93)90152-e.
2
Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.重度血管性血友病患者对去氨加压素的释放作用不敏感:这证明去氨加压素诱导的血浆因子VIII增加并非继发于血浆血管性血友病因子的增加。
Br J Haematol. 1994 Feb;86(2):333-7. doi: 10.1111/j.1365-2141.1994.tb04735.x.
3
Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease.血管性血友病中血管壁对去氨加压素和静脉阻塞的分泌反应。
Acta Haematol Pol. 1994;25(3):261-8.
4
Impaired release of tissue plasminogen activator (t-PA) following DDAVP infusion in von Willebrand's disease with low platelet von Willebrand factor content.在血管性血友病患者中,若血小板血管性血友病因子含量较低,输注去氨加压素后组织型纤溶酶原激活物(t-PA)释放受损。
Blood Coagul Fibrinolysis. 1992 Apr;3(2):149-53. doi: 10.1097/00001721-199204000-00003.
5
1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus.1-去氨基-8-D-精氨酸加压素(DDAVP)用于先天性肾性尿崩症患者。
Neth J Med. 1993 Aug;43(1-2):5-12.
6
Urokinase-type plasminogen activator release after DDAVP in von Willebrand disease: different behaviour of plasminogen activators according to the synthesis of von Willebrand factor.血管性血友病患者使用去氨加压素后尿激酶型纤溶酶原激活剂的释放:根据血管性血友病因子的合成情况,纤溶酶原激活剂的行为不同。
Thromb Res. 1992 Jun 1;66(5):517-26. doi: 10.1016/0049-3848(92)90306-u.
7
Evidence of a local mechanism for desmopressin-induced tissue-type plasminogen activator release in human forearm.
Blood. 1998 Jan 15;91(2):529-37.
8
Fibrinolytic and haemostatic responses to desamino-D-arginine vasopressin (DDAVP) administered by intravenous and subcutaneous routes in healthy subjects.健康受试者经静脉和皮下途径给予去氨基-D-精氨酸加压素(DDAVP)后的纤溶和止血反应。
Thromb Haemost. 1988 Feb 25;59(1):34-9.
9
Endothelial stimulation by DDAVP in von Willebrand's disease and haemophilia.去氨加压素对血管性血友病和血友病患者内皮细胞的刺激作用
Haemostasis. 1986;16(1):15-9. doi: 10.1159/000215264.
10
DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.去氨加压素对甲型血友病携带者的输注:血浆凝血因子 VIII 和血管性血友病因子的不同表现
Blood Coagul Fibrinolysis. 1996 Jul;7(5):549-53.

引用本文的文献

1
Tachyphylaxis and reproducibility of desmopressin response in perioperative persons with nonsevere hemophilia A: implications for clinical practice.去氨加压素对非重度甲型血友病围手术期患者反应的快速耐受性和可重复性:对临床实践的影响
Res Pract Thromb Haemost. 2024 Mar 5;8(3):102367. doi: 10.1016/j.rpth.2024.102367. eCollection 2024 Mar.
2
Desmopressin as a hemostatic and blood sparing agent in bleeding disorders.去氨加压素在出血性疾病中的止血和节血作用。
Eur J Haematol. 2023 May;110(5):470-479. doi: 10.1111/ejh.13930. Epub 2023 Feb 12.
3
Current controversies in the diagnosis and management of von Willebrand disease.
血管性血友病诊断与管理中的当前争议
Ther Adv Hematol. 2015 Aug;6(4):209-16. doi: 10.1177/2040620715587879.